



April 29, 2020

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Madam/ Sir,

**Subject: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides develops and commences export of Favipiravir Antiviral Tablets”**

Thanking you,

Yours faithfully,  
For **Strides Pharma Science Limited**

A handwritten signature in blue ink that reads 'Manjula R.'.

**Manjula Ramamurthy**  
Company Secretary



Encl. As above

**Strides Pharma Science Limited**  
(Formerly Strides Shasun Limited)  
CIN: L24230MH1990PLC057062

**Corp Off:** Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India  
Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

**Regd Off:** 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India  
Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

---

## Strides develops and commences export of Favipiravir Antiviral Tablets

- *Favipiravir tablets have demonstrated positive outcomes in Covid-19 treatment globally*
  - *Strides is the first Indian Company to have commenced export of Favipiravir tablets*
  - *Initial supplies to 3 GCC countries to treat patients under their Covid-19 procurement program*
  - *Strides to immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available to Indian patients expeditiously*
- 

**Bangalore, April 29, 2020** - Strides Pharma Science Limited (Strides or Company), a global pharmaceutical company today announced that it has developed and commercialized Favipiravir Antiviral tablets. The product is a generic version of Avigan® of Toyama Chemical, Japan.

Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan. In February 2020, post the outbreak of Novel Coronavirus(Covid-19), Favipiravir was studied in China and several other countries as an experimental treatment of Covid-19. The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients.

Strides has developed Favipiravir tablets in 400mg and 200mg strengths for convenient dosage administration. The product is currently being exported to GCC countries to treat patients under their treatment program for Covid-19. Strides will also immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available to Indian patients expeditiously.

Favipiravir tablets are being manufactured at Strides' flagship facility in Bangalore, India. The facility can produce up to 6 billion units of solid orals annually and is approved by USFDA, MHRA, WHO, TGA among others. Strides has also entered into a preferred arrangement with a leading Indian API manufacturer for the supplies of Favipiravir API. The partner has already commercialized the Favipiravir API from its USFDA, KFDA, PMDA and WHO approved manufacturing facility and has capabilities to manufacture the Favipiravir API from its Key Starting Material (KSM) in-house.

Commenting on the development, **Dr R Ananthanarayanan, CEO and Managing Director**, stated *"We are pleased to be the First Indian Company to develop and commercially launch Favipiravir tablets for the global markets. This development reinforces our commitment to play a substantial role in society by bringing affordable and quality healthcare to millions of people around the globe. Favipiravir has already demonstrated positive outcomes in several studies on Covid-19 patients, and we are hopeful that the treatment regime with Favipiravir would brace up our fight against this virus. He further added, "Favipiravir is a complex drug to make, while we are manufacturing the tablets in-house, we are also excited to partner with the API manufacturer such that our supply chain remains secured up to the key starting material."*

Strides is amongst the leading Indian suppliers of drugs in the anti-retroviral, anti-malarial, Hepatitis and other infectious disease drug segments. The Company has always been on the forefront in the fight against global pandemics and commercialized many antivirals to bring the best treatments at an affordable cost to patients world over. Strides is also an approved supplier to Institutionally-funded aid projects and Global Procurement Agencies like USAID, Global Fund, PEPFAR (The US President's Emergency Plan for AIDS Relief), UNICEF, WHO, Pan American Health Organization (PAHO), United Nations Development Program(UNDP), Population Services International (PSI), Chemeonics, PFSCM, amongst others.

## About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at [www.strides.com](http://www.strides.com)

## For further information, please contact:

### Strides

#### **Badree Komandur**

Executive Director - Finance

+91 80 6784 0747

### Investor Relations:

**Kannan. N:** +91 98450 54745

**Vikesh Kumar:** +91 80 6784 0827

**Sandeep Baid:** +91 80 6784 0791

Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

### Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi  
Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bangalore – 560 076

### PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

K Priya: +91 95354 25418

[priya@fortunapr.com](mailto:priya@fortunapr.com)